INBRX-106

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Jun '27

INBXPhase 2$1.5B

INBRX-106 Phase 2 Est. Readout

INBRX-106• Head and Neck Squamous Cell Carcinoma (HNSCC)12

Jun 2027~Estimated

00%

Competitive Landscape

0 competitors in Head and Neck Squamous Cell Carcinoma (HNSCC)

Drug Information

Target Indication

Head and Neck Squamous Cell Carcinoma (HNSCC)

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

INBX

Inhibrx Biosciences, Inc.

Related Pipeline

Conventional Chondrosarcoma

Solid Tumor

Solid Tumor

Solid Tumor

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts